A mimotope peptide of Aβ42 fibril-specific antibodies with Aβ42 fibrillation inhibitory activity induces anti-Aβ42 conformer antibody response by a displayed form on an M13 phage in mice

Journal of Neuroimmunology

Volumn 236, Issue 1-2, 2011, Pages 27-38

  Tanaka, Koichi ^a   Nishimura, Masaaki ^a   Yamaguchi, Yuya ^a   Hashiguchi, Shuhei ^a   Takiguchi, Sho ^a   Yamaguchi, Makoto ^a   Tahara, Haruna ^a   Gotanda, Takuma ^a   Abe, Risa ^a   Ito, Yuji ^a   Sugimura, Kazuhisa ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Amyloid beta; Human antibody; Mimotope peptide; Peptide mimics; Phage display library; Vaccine

Indexed keywords

AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; IMMUNOGLOBULIN G ANTIBODY; PEPTIDE; TAT B6 C15 PEPTIDE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MOTIF; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; AMYLOID; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIBODY SPECIFICITY; BACTERIOPHAGE M13; CELL LINE, TUMOR; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; MOLECULAR MIMICRY; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; SINGLE-CHAIN ANTIBODIES;

EID: 79960183340     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.04.010     Document Type: Article

References (43)

1. Bacskai B.J., Kajdasz S.T., Christie R.H., Carter C., Games D., Seubert P., Schenk D., Hyman B.T. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat. Med. 2001, 7:369-372.
2. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Lieberburg I., Motter R., Nguyen M., Soriano F., Vasquez N., Weiss K., Welch B., Seubert P., Schenk D., Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 2000, 6:916-919.
3. Billings L.M., Oddo S., Green K.N., McGaugh J.L., LaFerla F.M. Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005, 45:675-688.
4. Brody D.L., Holtzman D.M. Active and passive immunotherapy for neurodegenerative disorders. Annu. Rev. Neurosci. 2008, 31:175-193.
5. Brussow H. Phage therapy: the Escherichia coli experience. Microbiology 2005, 151:2133-2140.
6. Chyung J.H., Selkoe D.J. Inhibition of receptor-mediated endocytosis demonstrates generation of amyloid beta-protein at the cell surface. J. Biol. Chem. 2003, 278:51035-51043.
7. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001, 98:8850-8855.
8. Dodart J.C., Bales K.R., Gannon K.S., Greene S.J., DeMattos R.B., Mathis C., DeLong C.A., Wu S., Wu X., Holtzman D.M., Paul S.M. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 2002, 5:452-457.
9. Frenkel D., Solomon B. Filamentous phage as vector-mediated antibody delivery to the brain. Proc Natl Acad Sci USA 2002, 99:5675-5679.
10. Fukumoto T., Torigoe N., Kawabata S., Murakami M., Uede T., Nishi T., Ito Y., Sugimura K. Peptide mimics of the CTLA4-binding domain stimulate T-cell proliferation. Nat. Biotechnol. 1998, 16:267-270.
11. Gejima R., Tanaka K., Nakashima T., Hashiguchi S., Ito Y., Yoshizaki K., Sugimura K. Human single-chain Fv (scFv) antibody specific to human IL-6 with the inhibitory activity on IL-6-signaling. Hum. Antibodies 2002, 11:121-129.
12. Harmeier A., Wozny C., Rost B.R., Munter L.M., Hua H., Georgiev O., Beyermann M., Hildebrand P.W., Weise C., Schaffner W., Schmitz D., Multhaup G. Role of amyloid-beta glycine 33 in oligomerization, toxicity, and neuronal plasticity. J. Neurosci. 2009, 29:7582-7590.
13. Hartman R.E., Izumi Y., Bales K.R., Paul S.M., Wozniak D.F., Holtzman D.M. Treatment with an amyloid-beta antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. J. Neurosci. 2005, 25:6213-6220.
14. Hashiguchi S., Nakashima T., Nitani A., Yoshihara T., Yoshinaga K., Ito Y., Maeda Y., Sugimura K. Human Fc epsilon RIalpha-specific human single-chain Fv (scFv) antibody with antagonistic activity toward IgE/Fc epsilon RIalpha-binding. J. Neurosci. 2003, 133:43-49.
15. Hashiguchi S., Yamaguchi Y., Takeuchi O., Akira S., Sugimura K. Immunological basis of M13 phage vaccine: regulation under MyD88 and TLR9 signaling 2010, Biochem Biophys Res Commun.
16. Holtzman D.M. Alzheimer's disease: Moving towards a vaccine. Nature 2008, 454:418-420.
17. Jan A., Gokce O., Luthi-Carter R., Lashuel H.A. The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity. J. Biol. Chem. 2008, 283:28176-28189.
18. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P., Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000, 408:979-982.
19. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
20. Klyubin I., Betts V., Welzel A.T., Blennow K., Zetterberg H., Wallin A., Lemere C.A., Cullen W.K., Peng Y., Wisniewski T., Selkoe D.J., Anwyl R., Walsh D.M., Rowan M.J. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J. Neurosci. 2008, 28:4231-4237.
21. Kotilinek L.A., Bacskai B., Westerman M., Kawarabayashi T., Younkin L., Hyman B.T., Younkin S., Ashe K.H. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J. Neurosci. 2002, 22:6331-6335.
22. Kurzepa A., Dabrowska K., Skaradzinski G., Gorski A. Bacteriophage interactions with phagocytes and their potential significance in experimental therapy. Clin. Exp. Med. 2009, 9:93-100.
23. Ladiwala A.R., Lin J.C., Bale S.S., Marcelino-Cruz A.M., Bhattacharya M., Dordick J.S., Tessier P.M. Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Abeta into off-pathway conformers. J. Biol. Chem. 2010, 285:24228-24237.
24. Lee E.B., Leng L.Z., Zhang B., Kwong L., Trojanowski J.Q., Abel T., Lee V.M. Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J. Biol. Chem. 2006, 281:4292-4299.
25. LeVine H. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci. 1993, 2:404-410.
26. Li K., Chen Y., Li S., Nguyen H.G., Niu Z., You S., Mello C.M., Lu X., Wang Q. Chemical modification of M13 bacteriophage and its application in cancer cell imaging. Bioconjug. Chem. 2010, 21:1369-1377.
27. Luhrs T., Ritter C., Adrian M., Riek-Loher D., Bohrmann B., Dobeli H., Schubert D., Riek R. 3D structure of Alzheimer's amyloid-beta(1-42) fibrils. Proc Natl Acad Sci USA 2005, 102:17342-17347.
28. Luhrs T., Zahn R., Wuthrich K. Amyloid formation by recombinant full-length prion proteins in phospholipid bicelle solutions. J. Mol. Biol. 2006, 357:833-841.
29. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408:982-985.
30. Munter L.M., Voigt P., Harmeier A., Kaden D., Gottschalk K.E., Weise C., Pipkorn R., Schaefer M., Langosch D., Multhaup G. GxxxG motifs within the amyloid precursor protein transmembrane sequence are critical for the etiology of Abeta42. Embo J. 2007, 26:1702-1712.
31. Oddo S., Vasilevko V., Caccamo A., Kitazawa M., Cribbs D.H., LaFerla F.M. Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J. Biol. Chem. 2006, 281:39413-39423.
32. Salloway S., Sperling R., Gilman S., Fox N.C., Blennow K., Raskind M., Sabbagh M., Honig L.S., Doody R., van Dyck C.H., Mulnard R., Barakos J., Gregg K.M., Liu E., Lieberburg I., Schenk D., Black R., Grundman M. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009, 73:2061-2070.
33. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
34. Schneeberger A., Mandler M., Otawa O., Zauner W., Mattner F., Schmidt W. Development of AFFITOPE vaccines for Alzheimer's disease (AD)-from concept to clinical testing. J. Nutr. Health Aging 2009, 13:264-267.
35. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
36. Smith G.P., Scott J.K. Libraries of peptides and proteins displayed on filamentous phage. Methods Enzymol. 1993, 217:228-257.
37. Solomon B. Active immunization against Alzheimer's beta-amyloid peptide using phage display technology. Vaccine 2007, 25:3053-3056.
38. Stine W.B., Dahlgren K.N., Krafft G.A., LaDu M.J. In vitro characterization of conditions for amyloid-beta peptide oligomerization and fibrillogenesis. J. Biol. Chem. 2003, 278:11612-11622.
39. Wadia J.S., Dowdy S.F. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv. Drug Deliv. Rev. 2005, 57:579-596.
40. Wilcock D.M., Rojiani A., Rosenthal A., Subbarao S., Freeman M.J., Gordon M.N., Morgan D. Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J. Neuroinflammation 2004, 1:24.
41. Wilcock D.M., Alamed J., Gottschall P.E., Grimm J., Rosenthal A., Pons J., Ronan V., Symmonds K., Gordon M.N., Morgan D. Deglycosylated anti-amyloid-beta antibodies eliminate cognitive deficits and reduce parenchymal amyloid with minimal vascular consequences in aged amyloid precursor protein transgenic mice. J. Neurosci. 2006, 26:5340-5346.
42. Yoshihara T., Takiguchi S., Kyuno A., Tanaka K., Kuba S., Hashiguchi S., Ito Y., Hashimoto T., Iwatsubo T., Tsuyama S., Nakashima T., Sugimura K. Immunoreactivity of phage library-derived human single-chain antibodies to amyloid beta conformers in vitro. J. Biochem. 2008, 143:475-486.
43. Yoshinaga K., Matsumoto M., Torikai M., Sugyo K., Kuroki S., Nogami K., Matsumoto R., Hashiguchi S., Ito Y., Nakashima T., Sugimura K. Ig L-chain shuffling for affinity maturation of phage library-derived human anti-human MCP-1 antibody blocking its chemotactic activity. J. Biochem. 2008, 143:593-601.